Abstract
Biosimilars are regulated by the centralized marketing authorization procedure co-ordinated by the European Medicines Agency (EMA). Marketing authorization is granted by the Commission of the European Union (EU). Thus, each biosimilar has one regulatory assessment as well as the same product information and conditions of use in the EU. The current regulatory framework is a result of 20 years evolution of legislation and regulatory guidelines. The concept of biosimilarity is based on the long experience of comparability studies of individual biological products after manufacturing changes. Therefore, the development of a biosimilar is an extensive comparability exercise with head-to-head comparisons to its reference product that must have a full dossier of quality, safety and efficacy. For the sake of global development, the current guidance allows the use of a reference sourced from a non-EU country in certain non-clinical and clinical studies provided that it can be shown to be a relevant as a comparator. The high similarity of a biosimilar and its reference is demonstrated by physico-chemical and structural as well as in vitro functional comparability studies. Non-clinical in vivo studies are rarely needed. The extent of clinical studies depends on the possibilities to demonstrate high similarity by analytical tests. When the high analytical similarity has been established and the comparable pharmacokinetics and -dynamics, safety and efficacy have been demonstrated in one therapeutic indication, extrapolation safety and efficacy to other indications is expected. Several national regulatory agencies endorse physician-guided switches between biosimilars and reference products without additional clinical trials.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
van Aerts L, De Smet K, Reichmann G, et al. Biosimilars entering the clinic without animal studies: a paradigm shift in the European Union. mAbs. 2014;6:1155–62.
Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohn’s Colitis. 2017;2016:26–34.
Ebbers H, Crow S, Vulto A, Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol. 2012;30:1186–90.
EMA. History of EMA. 2017a. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000628.jsp&mid=WC0b01ac058087addd. Accessed 24 Oct 2017.
EMA. Committee for medicinal products for human use (CHMP). 2017b. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000094.jsp&mid=WC0b01ac0580028c79. Accessed 9 Dec 2017.
EMA. Multidisciplinary guidelines: biosimilar. 2017c. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c. Accessed 25 Nov 2017.
EMA. ICH guideline Q8 (R2) on pharmaceutical development. 2017d. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002872.pdf. Accessed 9 Dec 2017.
EMA. Remsima: public assessment report. 2017e. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002576/WC500151486.pdf. Accessed 9 Dec 2017.
EMA. Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 Rev. 1. 2017f. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001378.jsp&mid=WC0b01ac058002958c. Accessed 9 Dec 2017.
EMA. Guideline on Immunogenicity assessment of therapeutic proteins. 2017g. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/06/WC500228861.pdf. Accessed 9 Dec 2017.
EMA. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. 2017h. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf. Accessed 9 Dec 2017.
EMA. QRD general principles regarding the SmPC information for a generic/hybrid/biosimilar product. 2017i. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/05/WC500127589.pdf. Accessed 9 Dec 2017.
EMA. European public assessment reports. 2017j. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124. Accessed 10 Dec 2017.
EMA. Biosimilar medicines. 2017k. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp&mid=WC0b01ac0580bb8fda. Accessed 10 Dec 2017.
EMEA. Concept paper on the development of a committee of proprietary medicinal products (CPMP) guideline on the comparability of biotechnology-derived medicinal products. 1998. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003966.pdf. Accessed 23 Oct 2017.
EMEA. Guideline on the comparability of medicinal products containing biotechnology-derived proteins as active substance. Non-clinical and clinical issues. 2003. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003963.pdf. Accessed 23 Oct 2017.
EudraLex. Volume 1 - pharmaceutical legislation for medicinal products for human use. 2017. https://ec.europa.eu/health/documents/eudralex/vol-1_en. Accessed 9 Dec 2017.
European Commission. A guideline on summary of product characteristics (SmPC). 2009.
European Commission. Directive 2001/83/EC of the European parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use (consolidated version). 2017a. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf.
European Commission. A guideline on the summary of product characteristics. 2017b. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. Accessed 9 Dec 2017.
European Commission. Commission delegated regulation (EU)2016/161. 2017c. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2016_161/reg_2016_161_en.pdf. Accessed 10 Dec 2017.
European Commission, DG Enterprise and Industry. What you need to know about biosimilar medicinal products. Process on corporate responsibility in the field of pharmaceuticals access to medicines in Europe. A consensus Information Document. 2013. http://europa.eu/geninfo/query/resultaction.jsp?query_source=GROWTH&QueryText=biosimilars&op=Search&swlang=en& form_build_id=form-CA4kk1hS9th2Qw_AyEvYWFKAUUlCNvY6kFflINvXlD4&form_id= nexteuropa_europa_search_search_form. Accessed 28 Oct 2017.
European Union. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. 2017. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32010L0063&from=EN. Accessed 9 Dec 2017.
FDA. Considerations in demonstrating interchangeability with a reference product. 2017. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. Accessed 10 Dec 2017.
Glintborg B, Sorensen I, Loft A, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–31.
Kurki P, Ekman N. Biosimilar regulation in the EU. Expert Rev Clin Pharmacol. 2015;8(5):649–59.
Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31:83–91.
Mack A. Norway, biosimilars in different funding systems. What works? GaBI J. 2015;4:90–2.
Medicines for Europe. Positioning statements on physician-led switching for biosimilar medicines. 2017. http://www.medicinesforeurope.com/wp-content/uploads/2017/03/M-Biosimilars-Overview-of-positions-on-physician-led-switching.pdf. Accessed 7 Dec 2017.
QuintilesIMS. The impact of biosimilar competition in Europe. 2017. http://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf. Accessed 29 Oct 2017.
Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28:363–72.
Vermeer N, Straus S, Mantel-Teeuwisse A, et al. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA adverse event reporting system (FAERS) and EudraVigilance data bases. Drug Saf. 2013;36:617–25.
Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124:3191–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Kurki, P., Ekman, N. (2018). EU Perspective on Biosimilars. In: Gutka, H., Yang, H., Kakar, S. (eds) Biosimilars. AAPS Advances in the Pharmaceutical Sciences Series, vol 34. Springer, Cham. https://doi.org/10.1007/978-3-319-99680-6_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-99680-6_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99679-0
Online ISBN: 978-3-319-99680-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)